Diacylglycerol kinase-ζ regulates mTORC1 and lipogenic metabolism in cancer cells through SREBP-1

[1]  I. Mérida,et al.  Diacylglycerol kinase α promotes 3D cancer cell growth and limits drug sensitivity through functional interaction with Src , 2014, Oncotarget.

[2]  P. Mischel,et al.  mTORC2 in the center of cancer metabolic reprogramming , 2014, Trends in Endocrinology & Metabolism.

[3]  C. Yuh,et al.  Diacylglycerol lipase regulates lifespan and oxidative stress response by inversely modulating TOR signaling in Drosophila and C. elegans , 2014, Aging cell.

[4]  S. Gee,et al.  Increased diacylglycerol kinase ζ expression in human metastatic colon cancer cells augments Rho GTPase activity and contributes to enhanced invasion , 2014, BMC Cancer.

[5]  Eric Lagasse,et al.  mTOR pathway in colorectal cancer: an update , 2013, Oncotarget.

[6]  T. Hornberger,et al.  The Role of Diacylglycerol Kinase ζ and Phosphatidic Acid in the Mechanical Activation of Mammalian Target of Rapamycin (mTOR) Signaling and Skeletal Muscle Hypertrophy* , 2013, The Journal of Biological Chemistry.

[7]  I. Mérida,et al.  Transient PKC&agr; shuttling to the immunological synapse is governed by DGK&zgr; and regulates L-selectin shedding , 2013, Journal of Cell Science.

[8]  E. Nakakura,et al.  Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors , 2013, Oncogene.

[9]  S. Klein,et al.  Mice with an adipocyte-specific lipin 1 separation-of-function allele reveal unexpected roles for phosphatidic acid in metabolic regulation , 2012, Proceedings of the National Academy of Sciences.

[10]  J. Ellenberg,et al.  Mitotic lamin disassembly is triggered by lipid-mediated signaling , 2012, The Journal of cell biology.

[11]  R. Hammer,et al.  Insulin stimulation of SREBP-1c processing in transgenic rat hepatocytes requires p70 S6-kinase , 2012, Proceedings of the National Academy of Sciences.

[12]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[13]  Jeremy S Logue,et al.  Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy. , 2012, Genes & development.

[14]  I. Mérida,et al.  Diacylglycerol kinase ζ controls diacylglycerol metabolism at the immunological synapse , 2011, Molecular biology of the cell.

[15]  Sarat Chandarlapaty,et al.  mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. , 2011, Cancer discovery.

[16]  Anne E Carpenter,et al.  mTOR Complex 1 Regulates Lipin 1 Localization to Control the SREBP Pathway , 2011, Cell.

[17]  Mee-Sup Yoon,et al.  Phosphatidic Acid Activates Mammalian Target of Rapamycin Complex 1 (mTORC1) Kinase by Displacing FK506 Binding Protein 38 (FKBP38) and Exerting an Allosteric Effect* , 2011, The Journal of Biological Chemistry.

[18]  Claudio R. Santos,et al.  Regulation of the SREBP transcription factors by mTORC1. , 2011, Biochemical Society transactions.

[19]  B. Manning,et al.  mTOR links oncogenic signaling to tumor cell metabolism , 2011, Journal of Molecular Medicine.

[20]  E. Rozengurt.  Protein kinase D signaling: multiple biological functions in health and disease. , 2011, Physiology.

[21]  D. Sabatini,et al.  mTOR: from growth signal integration to cancer, diabetes and ageing , 2010, Nature Reviews Molecular Cell Biology.

[22]  G. Mills,et al.  Rapamycin Regulates Stearoyl CoA Desaturase 1 Expression in Breast Cancer , 2010, Molecular Cancer Therapeutics.

[23]  D. Sabatini,et al.  Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. , 2010, Journal of medicinal chemistry.

[24]  Qicheng Ma,et al.  Activation of a metabolic gene regulatory network downstream of mTOR complex 1. , 2010, Molecular cell.

[25]  R. Schneider,et al.  Mitotic Raptor Promotes mTORC1 Activity, G2/M Cell Cycle Progression, and Internal Ribosome Entry Site-Mediated mRNA Translation , 2010, Molecular and Cellular Biology.

[26]  S. Horvath,et al.  EGFR Signaling Through an Akt-SREBP-1–Dependent, Rapamycin-Resistant Pathway Sensitizes Glioblastomas to Antilipogenic Therapy , 2009, Science Signaling.

[27]  Suimin Qiu,et al.  Targeted Inhibition of Mammalian Target of Rapamycin Signaling Inhibits Tumorigenesis of Colorectal Cancer , 2009, Clinical Cancer Research.

[28]  D. A. Foster.  Phosphatidic acid signaling to mTOR: signals for the survival of human cancer cells. , 2009, Biochimica et biophysica acta.

[29]  H. Lane,et al.  Optimal targeting of the mTORC1 kinase in human cancer. , 2009, Current opinion in cell biology.

[30]  L. Cocco,et al.  Involvement of nuclear PLCβl in lamin B1 phosphorylation and G2/M cell cycle progression , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  M. Simons,et al.  Syndecan-4 regulates subcellular localization of mTOR Complex2 and Akt activation in a PKCalpha-dependent manner in endothelial cells. , 2008, Molecular cell.

[32]  Claudio R. Santos,et al.  SREBP Activity Is Regulated by mTORC1 and Contributes to Akt-Dependent Cell Growth , 2008, Cell metabolism.

[33]  K. Inoki,et al.  Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling , 2008, The EMBO journal.

[34]  A. Newton,et al.  The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C , 2008, The EMBO journal.

[35]  H. A. Brown,et al.  Phospholipase D1 is an effector of Rheb in the mTOR pathway , 2008, Proceedings of the National Academy of Sciences.

[36]  X. Deng,et al.  SREBPs: the crossroads of physiological and pathological lipid homeostasis , 2008, Trends in Endocrinology & Metabolism.

[37]  J. LoPiccolo,et al.  Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[38]  M. Carr,et al.  Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR , 2008, Oncogene.

[39]  Michal A. Kurowski,et al.  Transcriptome Profile of Human Colorectal Adenomas , 2007, Molecular Cancer Research.

[40]  C. Otis,et al.  PLD1 is overexpressed in an ER-negative MCF-7 cell line variant and a subset of phospho-Akt-negative breast carcinomas , 2007, British Journal of Cancer.

[41]  I. Mérida,et al.  Proteomics identification of sorting nexin 27 as a diacylglycerol kinase zeta-associated protein: new diacylglycerol kinase roles in endocytic recycling. , 2007, Molecular & cellular proteomics : MCP.

[42]  Raffaele Fronza,et al.  Global alterations in mRNA polysomal recruitment in a cell model of colorectal cancer progression to metastasis. , 2006, Carcinogenesis.

[43]  D. Sabatini,et al.  Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. , 2006, Molecular cell.

[44]  Gordon B Mills,et al.  mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.

[45]  Steven P. Gygi,et al.  mTOR and S6K1 Mediate Assembly of the Translation Preinitiation Complex through Dynamic Protein Interchange and Ordered Phosphorylation Events , 2005, Cell.

[46]  I. Mérida,et al.  Modulation of the Mammalian Target of Rapamycin Pathway by Diacylglycerol Kinase-produced Phosphatidic Acid* , 2005, Journal of Biological Chemistry.

[47]  D. A. Foster,et al.  Phospholipase D confers rapamycin resistance in human breast cancer cells , 2003, Oncogene.

[48]  M. Topham,et al.  Association of diacylglycerol kinase ζ with protein kinase C α , 2003, The Journal of Cell Biology.

[49]  J. Lawrence,et al.  Insulin-stimulated phosphorylation of lipin mediated by the mammalian target of rapamycin , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[50]  Jie Chen,et al.  Phosphatidic Acid-Mediated Mitogenic Activation of mTOR Signaling , 2001, Science.

[51]  J. P. Walsh,et al.  Selectivity of the diacylglycerol kinase inhibitor 3-[2-(4-[bis-(4-fluorophenyl)methylene]-1-piperidinyl)ethyl]-2, 3-dihydro-2-thioxo-4(1H)quinazolinone (R59949) among diacylglycerol kinase subtypes. , 2000, Biochemical pharmacology.

[52]  Y. Hannun,et al.  Dual role of ceramide in the control of apoptosis following IL-2 withdrawal. , 1998, Journal of immunology.

[53]  S. Schreiber,et al.  Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[54]  W. J. Dyer,et al.  A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.

[55]  K. Cai.  Title : Increased Diacylglycerol Kinase zeta Expression in Human Metastatic Colon Cancer Cells Augments Rho GTPase Activity and Contributes to Enhanced Invasion , 2013 .

[56]  I. Mérida,et al.  Diacylglycerol kinases: at the hub of cell signalling. , 2008, The Biochemical journal.

[57]  L. Altucci,et al.  in human breast cancer cells , 2008 .

[58]  M. Topham,et al.  Association of diacylglycerol kinase zeta with protein kinase C alpha: spatial regulation of diacylglycerol signaling. , 2003, The Journal of cell biology.